Department of Clinical Laboratory, The Fourth Medical Centre, Chinese PLA General Hospital, No. 51 Fucheng Road, Beijing 100037, China.
Department of Orthopedics Surgery, Chinese PLA General Hospital, No. 51 Fucheng Road, Beijing 100037, China.
Can Respir J. 2023 Jan 12;2023:4119541. doi: 10.1155/2023/4119541. eCollection 2023.
There is currently limited evidence for a correlation between the recommended operation and overall survival (OS) in patients with advanced non-small-cell lung cancer (NSCLC).
NSCLC patients with stages III and IV, recommended for operation, were identified in the US National Cancer Institute Surveillance, Epidemiology, and End Results database (SEER).We used propensity score matching (PSM) and multivariable Cox proportional hazards regression to ensure the robustness of our findings. The cumulative rates of death were compared between patients with and without recommended operations using the Kaplan-Meier curves.
Operation was recommended for 3331 patients but was not performed in 912 (27.4%) patients (then on-operative group). After PSM, 553 pairs matched. Compared to the nonoperative group, the hazard ratios (HRs) in the operative group were 0.46 (95% CI 0.23-0.95 and =0.037) in stage IIIA and 0.54 (95% CI 0.42-0.68 and < 0.001) in stage IVA. However, in stages IIIB, IIIC, and IVB, the recommended operative group was not associated with better OS. The OS was not different in stage IIIA-N2, stage IVA-N1, and stage IVA-N3 patients between groups (=0.28, =0.14, and =0.79, respectively). Moreover, the recommended operative group had better OS than the nonoperative group in stage IIIA-N0 (=0.00085), stage IIIA-N1 (=0.009), stage IVA-N0 ( < 0.001), and stage IVA-N2 (=0.034).
Compared to the nonoperative group, recommended operation improved survival in NSCLC patients with stage IIIA-N0, stage IIIA-N1, stage IVA-N0, and stage IVA-N2. However, in stages IIIA-N2, IIIB, IIIC, IVA-N1, IVA-N3, and IVB, recommended operation did not lead to significantly improved survival time.
目前,晚期非小细胞肺癌(NSCLC)患者的推荐手术与总生存期(OS)之间的相关性证据有限。
在美国国家癌症研究所监测、流行病学和最终结果数据库(SEER)中确定了推荐手术的 III 期和 IV 期 NSCLC 患者。我们使用倾向评分匹配(PSM)和多变量 Cox 比例风险回归来确保我们发现的稳健性。使用 Kaplan-Meier 曲线比较有和无推荐手术患者的死亡率累积率。
建议对 3331 名患者进行手术,但有 912 名(27.4%)患者未进行手术(即非手术组)。经过 PSM 后,匹配了 553 对。与非手术组相比,手术组 IIIA 期的风险比(HR)为 0.46(95%CI 0.23-0.95 和 =0.037),IVA 期的 HR 为 0.54(95%CI 0.42-0.68 和 < 0.001)。然而,在 IIIB、IIIC 和 IVB 期,推荐手术组与更好的 OS 无关。在 IIIA-N2、IVA-N1 和 IVA-N3 患者中,两组之间的 OS 没有差异(=0.28、=0.14 和 =0.79,分别)。此外,与非手术组相比,推荐手术组在 IIIA-N0(=0.00085)、IIIA-N1(=0.009)、IVA-N0(<0.001)和 IVA-N2(=0.034)的 OS 更好。
与非手术组相比,推荐手术改善了 IIIA-N0、IIIA-N1、IVA-N0 和 IVA-N2 期 NSCLC 患者的生存。然而,在 IIIA-N2、IIIB、IIIC、IVA-N1、IVA-N3 和 IVB 期,推荐手术并没有显著延长生存时间。